<DOC>
	<DOC>NCT00309569</DOC>
	<brief_summary>Primarily, this clinical investigation compared overall survival and recurrence-free survival in patients with hormone receptor-negative breast cancer treated with pre- and postoperative chemotherapy vs. conventional postoperative treatment.</brief_summary>
	<brief_title>Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients with bioptically verified breast cancer Estrogen receptornegative status Age: &lt; 70 years WHO Performance Status &lt; 2 Laboratory parameters 1. hematopoiesis: &gt; 3500/l leukocytes, &gt; 100,000/l thrombocytes 2. renal function: creatinin &lt; 1.5mg% 3. hepatic function: GOT  2.5 x UNL 4. bilirubin: &lt; 2.0 mg % 5. metabolic parameters: Na, Ca, K in normal range &lt;/= 4 weeks interval since surgery Informed consent Patients with locally inoperable cancer, M1 Other preoperative tumorspecific radiotherapy, chemotherapy or endocrine treatment Pregnancy or lactation General contraindication against cytostatic treatment T4 cancer; inflammatory disease, simultaneous or sequential bilateral breast cancer Lacking compliance or understanding of disease Serious concomitant disease Second carcinoma or status post second carcinoma (except for treated squamous cell carcinoma of the skin or cervical carcinoma in situ)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 1999</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Epirubicine</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>